FCM
OCUL icon

Farallon Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Farallon Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$152K Hold
18,000
– – ﹤0.01% 155
2025
Q4 		$219K Buy
+18,000
New +$219K ﹤0.01% 132
2015
Q4 		– Sell
-271,200
Closed -$3.81M – 76
2015
Q3 		$3.81M Buy
271,200
+56,200
+26% +$1.13M 0.05% 70
2015
Q2 		$4.52M Buy
+215,000
New +$5.33M 0.06% 82

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Farallon Capital Management's OCUL Position: Q1 2026 in Review

Farallon Capital Management held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 18,000 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #155.

Farallon Capital Management first reported a position in OCUL in Q2 2015 and has held it in 4 quarters since. The position peaked at $4.52M in Q2 2015. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Farallon Capital Management held 18,000 shares of Ocular Therapeutix worth $152K as of Q1 2026.
  • Farallon Capital Management left its Ocular Therapeutix share count unchanged in Q1 2026.
  • Ocular Therapeutix made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #155 holding.
  • Farallon Capital Management first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 4 quarters since.
  • Farallon Capital Management's Ocular Therapeutix position peaked at $4.52M in Q2 2015.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.